Loading...
Ayurcann Holdings Corp.
AYUR.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.03
CA$0.00(0.00%)

Over the last four quarters, Ayurcann Holdings Corp. achieved steady financial progress, growing revenue from $5.81M in Q2 2023 to $8.31M in Q1 2024. Gross profit stayed firm with margins at 38% in Q1 2024 versus 33% in Q2 2023. Operating income totaled -$139452.00 in Q1 2024, maintaining a -2% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $86211.00. Net income rose to -$356711.00, with EPS at -$0.002. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan